论文部分内容阅读
目的对单纯性重症颅脑损伤病人应用重组生长激素,以观察生长激素对此类病人血糖的影响。方法前瞻性、随机将66例单纯性重症颅脑损伤病人分为对照组和实验组,两组病人都接受常规的治疗。实验组于受伤后第3天开始用重组生长激素,疗程10 d。分别测定两组在受伤后3～13 d 的血糖、糖耐量、血胰岛素(Is)的变化。结果两组的糖耐量值,在受伤后早期都出现异常,2周后实验组与对照组的糖耐量都恢复正常,两组对比无显著性差异。结论在单纯性重症颅脑损伤病人中每日使用8 u 重组生长激素不会加重颅脑损伤病人已有的糖耐量异常。
Objective To study the effect of growth hormone on blood glucose in patients with simple severe craniocerebral injury by using recombinant growth hormone. Methods A prospective, randomized 66 cases of simple severe craniocerebral injury patients were divided into control group and experimental group, both groups received routine treatment. The experimental group began to use recombinant growth hormone on the 3rd day after injury for 10 days. The changes of blood glucose, glucose tolerance and blood insulin (Is) in 3 ~ 13 d after injury were measured. Results The glucose tolerance of the two groups were abnormal in the early stage after injury. After two weeks, the glucose tolerance of the experimental group and the control group returned to normal. There was no significant difference between the two groups. Conclusions Daily use of 8 ug recombinant growth hormone in patients with simple severe craniocerebral injury does not exacerbate the existing impaired glucose tolerance in patients with craniocerebral injury.